Full text
Earnings transcript
Read the complete earnings call transcript.
OPCH
Option Care Health, Inc.
$21.31
0.2
(0.92%)
| Exchange: | NASDAQ |
| Market Cap: | 3.345B |
| Shares Outstanding: | 2.389M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Care Facilities | |||||
| CEO: | Luke Whitworth | |||||
| Full Time Employees: | 8000 | |||||
| Address: |
| |||||
| Website: | https://www.optioncarehealth.com |
Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses. They also provide immunoglobulin infusions for immune system deficiencies and treatments targeting chronic inflammatory disorders like Crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Furthermore, Option Care Health assists in managing the progression of neurological conditions such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy. They also administer infusion therapies for bleeding disorders and provide crucial support for women experiencing high-risk pregnancies. Other specialized infusion services encompass pain relief, chemotherapy, and respiratory care. Complementing these medical offerings, the company provides professional nursing services. Option Care Health, Inc. maintains its primary corporate office in Bannockburn, Illinois.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 4,302,324 | 4,998,202 | 5,649,519 |
| Gross Profit | 981,223 | 1,012,993 | 1,020,357 |
| EBITDA | 472,190 | 396,126 | 408,596 |
| Operating Income | 314,595 | 321,833 | 337,906 |
| Net Income | 267,090 | 211,823 | 207,585 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 3,217,035 | 3,421,743 | 3,455,769 |
| Total Liabilities | 1,795,363 | 2,017,505 | 2,129,376 |
| Total Stockholders Equity | 1,421,672 | 1,404,238 | 1,326,393 |
| Total Debt | 1,166,412 | 1,217,973 | 0 |
| Cash and Cash Equivalents | 343,849 | 412,565 | 232,624 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 371,295 | 323,392 | 258,447 |
| Capital Expenditure | -41,866 | 0 | 0 |
| Free Cash Flow | 329,429 | 323,392 | 258,447 |
| Net Income | 267,089.999 | 211,823 | 207,585 |
| Net Change in Cash | 49,663 | 68,716 | -179,941 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 7,631,353.471 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 7,787,412.525 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 7,702,602 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 636,596.350 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 649,614.568 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 642,539.798 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 445,465.318 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 457,341.953 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 450,887.402 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 1,044,694.076 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 1,066,057.779 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 1,054,447.642 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 2.760 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 2.800 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 2.730 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 6 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: Option Care Health reported strong results in Q2 2025, with revenue growth and improved profitability as highlighted in the earnings call transcript. Key metrics such as net income and operating cash flow demonstrate operational efficiency, supported by a broad therapeutic portfolio.
- Positive Earnings Call Sentiment: The Q2 2025 earnings call summary reflects confidence in the company’s strategic direction, with management emphasizing operational capabilities and consistent delivery on financial targets, which may bolster investor trust.
- Favorable Valuation Metrics: The forward P/E ratio (based on available estimates) suggests OPCH is reasonably valued compared to industry averages, indicating potential for sustained investor interest. Current price-to-sales ratio (TTM) also aligns with sector norms, supporting a stable valuation outlook.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates OPCH intrinsic value between $27.53 – $31.45 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about OPCH valuation
Is Option Care Health, Inc. (OPCH) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Option Care Health, Inc. (OPCH) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is OPCH a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OPCH trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is OPCH’s P/E ratio?
You can see OPCH’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for OPCH?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is OPCH a good long-term investment?
Whether OPCH fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
OPCH
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.92
Trading Metrics:
| Open: | 21.03 | Previous Close: | 21.11 | |
| Day Low: | 20.99 | Day High: | 21.36 | |
| Year Low: | 18.01 | Year High: | 36.8 | |
| Price Avg 50: | 24.03 | Price Avg 200: | 28.86 | |
| Volume: | 120159 | Average Volume: | 2.867M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeOPCH full analysis
Welcome to MARKETSNAP’s SWOT analysis for Option Care Health, also known by its ticker OPCH. If you’re a long-term investor looking to build wealth through smart stock picks, you’re in the right place. Today, we’re diving deep into a company that might not be a household name for everyone, so let’s start with a quick overview before we unpack the latest developments, financials, and a full SWOT breakdown to help you decide if this stock fits your portfolio. Option Care…
